Green, Ph.D.

Oluyinka M. Green, Ph.D.

Technology Specialist
Boston

I apply my passion for science to providing clients with strategic patent preparation and prosecution support.

Oluyinka Green is a technology specialist in the Intellectual Property Practice Group where she utilizes her prior work experience at pharmaceutical and biotech companies as a research medicinal chemist in small molecule therapeutics in infectious disease, neurology, and oncology therapy areas.

Yinka has experience in drug research and development including target selection, structure-based design, triaging outputs from high throughput screening, hit-to-lead identification, and lead optimization to viable clinical candidate drugs. She was a post-doctoral fellow at the University of Edinburgh, Scotland, and Purdue University in the areas of synthetic organic chemistry and total chemical synthesis. She is a named inventor on 10 issued/pending patent documents and has authored or co-authored 30 articles in peer-reviewed journals.

Prior to joining Foley Hoag, Yinka worked as a technology specialist at another law firm where she assisted her clients with the preparation of domestic and international patent applications, and analyses of patent documents for freedom-to-operate, and patentability investigations.

Education

  • Northeastern University, M.S., Regulatory Affairs
  • University of Manchester, Institute of Science and Technology (England), Ph.D., M.Sc., Chemistry,
  • University of Ibadan (Nigeria), B.Sc., Chemistry, with honors

Bar and Court Admissions

COURT ADMISSIONS
  • U.S. Patent & Trademark Office (Agency)

Publications

Yinka is a named inventor on 10 issued/pending patent documents and has authored or co-authored 30 articles in peer-reviewed journals, including:
  • GS Basarab; PJ Hill; CE Garner; K Hull; OM Green; BA Sherer; PB Dangel; JI Manchester; S Bist; S Hauck; F Zhou; M Uria-Nickelsen; R Illingworth; R Alm; M Rooney; AE Eakin, "Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate," Journal of Medicinal Chemistry, 2014, 57 (14), 6060-6082
  • SP Kawatkar; TA Keating; NB Olivier; JN Breen; OM Green; SY Guler; MF Hentemann; JT Loch; AR McKenzie; JV Newman; LG Otterson; G Martínez-Botella, "Antibacterial inhibitors of gram-positive thymidylate kinase: structure–activity relationships and chiral preference of a new hydrophobic binding region," Journal of Medicinal Chemistry, 2014, 57 (11), 4584-4597
  • G Martínez-Botella; JT Loch; OM Green; SP Kawatkar; NB Olivier; PA Boriack-Sjodin; TA Keating, "Sulfonylpiperidines as novel, antibacterial inhibitors of Gram-positive thymidylate kinase (TMK)," Bioorganic & medicinal chemistry letters, 2013, 23 (1), 169-173
  • M Uria-Nickelsen; A Blodgett; H Kamp; A Eakin; B Sherer; O Green, "Novel DNA gyrase inhibitors: Microbiological characterisation of pyrrolamides," International journal of antimicrobial agents, 2013, 41 (1), 28-35

Honors & Involvement

HONORS
  • CD/FTIM Infection Discovery Award (2006-AstraZeneca) 
  • Hit Evaluation Team: Special Team Contributor in Infection (2006-AstraZeneca) 
  • Gyrase B Inhibition Program: Outstanding Team Achievement (2005- AstraZeneca)